EYPT
Eyepoint Inc
NASDAQ · Pharmaceuticals
$13.30
+0.57 (+4.48%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 63.63M | 60.36M | 205.52M | 211.34M | 213.20M |
| Net Income | -192,447,167 | -164,297,524 | 48.20M | 52.60M | 44.43M |
| EPS | — | — | — | — | — |
| Profit Margin | -302.4% | -287.3% | 23.5% | 24.9% | 20.8% |
| Rev Growth | +5.4% | +5.4% | +1.6% | -6.2% | +21.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 87.41M | 107.95M | 96.71M |
| Total Equity | — | — | 405.29M | 420.20M | 423.48M |
| D/E Ratio | — | — | 0.22 | 0.26 | 0.23 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -212,216,754 | -191,240,671 | 61.03M | 60.54M | 58.90M |
| Free Cash Flow | — | — | 35.62M | 38.74M | 42.58M |